Genomenon

Genomenon is the Ann Arbor genomics AI company that has built the most comprehensive curated database of human genomic evidence on the market. Founded in 2014 by Mark Kiel, a former U-M pathologist, Genomenon applies machine learning to the scientific literature and clinical data that describes how specific gene variants drive human disease, then packages that evidence into software that clinical labs and pharmaceutical companies use to interpret genetic tests and design precision therapies.

The technical workflow is unusually sophisticated. The company's Mastermind platform indexes millions of scientific articles and associates gene variants with specific diseases, therapies, and outcomes at a granularity that manual curation could never achieve. Clinical genetic testing labs use Mastermind to interpret variants in real patient samples. Pharmaceutical companies use the underlying evidence data to prioritize drug targets and design clinical trials for rare diseases and oncology programs.

Genomenon's position in Ann Arbor is a direct reflection of the city's combined strength in clinical research, medical informatics, and machine learning. Michigan Medicine is a top genomics and pathology center, and U-M's computational biology community runs deep. The company has been able to hire domain-fluent ML engineers who understand both the underlying science and the software engineering at a level that most Bay Area companies struggle to match.

For bioinformatics engineers, ML specialists, and clinical scientists who want to work at the intersection of genomics and real patient care, Genomenon offers an unusually clear mission and a product that ships directly into clinical workflows. The office is in Ann Arbor, the compensation is competitive, and the Ann Arbor lifestyle lets employees build serious careers without the cost pressures that define coastal biotech hubs.